Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Jun;29(6):930-939.
doi: 10.1038/s41431-021-00834-9. Epub 2021 Feb 26.

The impact of unsolicited findings in clinical exome sequencing, a qualitative interview study

Affiliations

The impact of unsolicited findings in clinical exome sequencing, a qualitative interview study

Vyne van der Schoot et al. Eur J Hum Genet. 2021 Jun.

Abstract

Unsolicited findings (UFs) in clinical exome sequencing are variants that are unrelated to the initial clinical question the DNA test was performed for, but that may nonetheless be of medical relevance to patients and/or their families. There is limited knowledge about the impact of UFs on patients' lives. In order to characterise patient perceptions of the impact of an UF, we conducted 20 semi-structured face-to-face interviews with patients and/or their relatives to whom an UF predisposing to oncological disease (n = 10) or predisposing to a cardiac condition (n = 10) had been disclosed. We have identified a psychological, physical and financial aspect of the perceived impact of UF disclosure in exome sequencing. Actionability, understanding, patients' pre-test health and social context were influencing factors, according to our participants. Although most expressed considerable psychological impact initially, all but one participant would choose to undergo genetic testing again, knowing what they know now. These novel findings provide insight in patients' perspectives on the impact of UF disclosure. Our study highlights the value of incorporating patients' perceptions in UF disclosure policy.

PubMed Disclaimer

Conflict of interest statement

The authors declare no competing interests.

Similar articles

Cited by

References

    1. Srivastava S, Love-Nichols JA, Dies KA, Ledbetter DH, Martin CL, Chung WK, et al. Meta-analysis and multidisciplinary consensus statement: exome sequencing is a first-tier clinical diagnostic test for individuals with neurodevelopmental disorders. Genet Med. 2019;21:2413–21. doi: 10.1038/s41436-019-0554-6. - DOI - PMC - PubMed
    1. Berg JS, Khoury MJ, Evans JP. Deploying whole genome sequencing in clinical practice and public health: meeting the challenge one bin at a time. Genet Med. 2011;13:499–504. doi: 10.1097/GIM.0b013e318220aaba. - DOI - PubMed
    1. Christenhusz GM, Devriendt K, Dierickx K. Secondary variants-in defense of a more fitting term in the incidental findings debate. Eur J Hum Genet. 2013;21:1331–4. doi: 10.1038/ejhg.2013.89. - DOI - PMC - PubMed
    1. Tan N, Amendola LM, O’Daniel JM, Burt A, Horike-Pyne MJ, Boshe L, et al. Is “incidental finding” the best term?: a study of patients’ preferences. Genet Med. 2017;19:176–81. doi: 10.1038/gim.2016.96. - DOI - PMC - PubMed
    1. van El CG, Cornel MC, Borry P, Hastings RJ, Fellmann F, Hodgson SV, et al. Whole-genome sequencing in health care. Recommendations of the European Society of Human Genetics. Eur J Hum Genet. 2013;21:S1–5. doi: 10.1038/ejhg.2013.219. - DOI - PMC - PubMed